Breakdown | |||||
TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
18.77M | 13.23M | 6.93M | 12.11M | 15.99M | 14.10M | Gross Profit |
10.01M | 10.42M | -3.53M | 2.82M | 4.88M | 3.37M | EBIT |
-3.73M | -6.85M | -9.78M | -1.88M | 966.00K | -1.28M | EBITDA |
-4.43M | -5.13M | -8.85M | -340.00K | 2.75M | 721.00K | Net Income Common Stockholders |
-4.80M | -5.41M | -8.50M | -1.16M | 2.10M | -1.92M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
8.82M | 904.00K | 4.43M | 9.21M | 6.93M | 6.86M | Total Assets |
39.45M | 31.37M | 28.29M | 30.08M | 34.13M | 28.59M | Total Debt |
479.00K | 4.47M | 740.00K | 881.00K | 766.00K | 5.00K | Net Debt |
-8.34M | 3.96M | -3.69M | -8.33M | -6.16M | -6.86M | Total Liabilities |
7.59M | 7.93M | 4.15M | 3.46M | 6.51M | 5.29M | Stockholders Equity |
31.85M | 23.44M | 24.14M | 26.63M | 27.61M | 23.30M |
Cash Flow | Free Cash Flow | ||||
-11.86M | -10.30M | -8.42M | 1.95M | -156.00K | -2.65M | Operating Cash Flow |
-10.70M | -9.60M | -7.90M | 2.86M | 370.00K | -1.89M | Investing Cash Flow |
-1.16M | -1.09M | -522.00K | -912.00K | -526.00K | -761.00K | Financing Cash Flow |
8.76M | 6.77M | 3.64M | 337.00K | 224.00K | 12.00K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
69 Neutral | $117.14B | 28.12 | 15.38% | 1.85% | 8.00% | 9.09% | |
54 Neutral | $5.31B | 3.28 | -45.10% | 2.80% | 16.76% | 0.02% | |
44 Neutral | AU$41.35M | ― | -19.31% | ― | 72.25% | 43.66% | |
43 Neutral | AU$79.91M | ― | ― | ― | -33.01% | ||
43 Neutral | AU$38.41M | ― | -75.39% | ― | ― | 44.29% | |
42 Neutral | AU$38.89M | ― | -43.63% | ― | -67.07% | -47.32% |
IDT Australia Limited reported a 30% increase in quarterly revenue, reaching $4.1 million, driven by new contract wins and a strong pipeline of potential contracts totaling $62 million. The company experienced significant growth in its Active Pharmaceutical Ingredients vertical, which is expected to positively impact its Advanced Therapies and Specialty Orals segments. Despite global trade uncertainties, IDT’s outlook remains positive, with new contracts and proposals indicating robust future growth opportunities.
IDT Australia Limited announced a change in the director’s interest in securities, with Geoffrey Sam acquiring additional ordinary fully paid shares through on-market trades. This acquisition increases his total holdings, potentially signaling confidence in the company’s future performance and stability, which may positively impact stakeholder perception.
IDT Australia Limited has secured a five-year, $3.2 million contract with Nacuity Pharmaceuticals for the manufacture of NPI-001, an investigational treatment for retinitis pigmentosa. This contract involves recommissioning IDT’s 4,000L Active Pharmaceutical Ingredient plant, making it the largest small molecule API facility in Australia, which strategically positions IDT to address potential drug shortages and expand its manufacturing capabilities.